Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
By J. Brandt, S. Close, S. Iturria, C. Payne, N. Farid, C. Ernest, D. R. Lachno, D. Salazar, K. Winters. Journal of Thrombosis and Haemostasis, 2007
776 citations recorded by the source corpus.
Subfields: Biochemistry, Cardiology and Cardiovascular Medicine, Pharmacology
View Paper: https://www.semanticscholar.org/paper/30600c5d834ece3dac7b780f73823d1f637fdce0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- M. Kazui
- Y. Nishiya
- T. Ikeda
- A. Kurihara
- N. Farid
- T. Ishizuka
- K. Hagihara
- O. Okazaki
Citations in the corpus
- Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. (2011, neutral): “BMI, median (range) 31 (15-66) 31 (15-60) .”
- Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite (2010, background): “…on the pharmacodynamic response of clopidogrel, and studies on the effect of genetic polymorphism of CYP2C19 on the clinical outcomes in patients treated with clopidogrel (Hulot et al., 2006; Suh et al., 2006; Brandt et al., 2007; Farid et al., 2007, 2008; Mega et al., 2009; Simon et al., 2009).”